DexCom CFO Departs; Interim Appointed, New Directors Elected

Ticker: DXCM · Form: 8-K · Filed: Sep 16, 2025 · CIK: 1093557

Dexcom INC 8-K Filing Summary
FieldDetail
CompanyDexcom INC (DXCM)
Form Type8-K
Filed DateSep 16, 2025
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: executive-departure, board-changes, interim-cfo

Related Tickers: DXCM

TL;DR

CFO OUT, interim IN. New board members join. #leadershipchange

AI Summary

DexCom, Inc. announced on September 14, 2025, the departure of its Chief Financial Officer, Parth Desai. The company has appointed Jerrod Hill as the interim CFO. Additionally, the board of directors has elected two new independent directors, Kevin J. McNamara and Steven J. Shulman, effective September 14, 2025.

Why It Matters

The departure of a CFO and the appointment of new directors can signal changes in financial strategy or governance, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in key executive positions and board composition can introduce uncertainty regarding future strategy and financial management.

Key Players & Entities

FAQ

Who has been appointed as the interim Chief Financial Officer of DexCom, Inc.?

Jerrod Hill has been appointed as the interim Chief Financial Officer.

When was the departure of Parth Desai as CFO announced?

The departure was reported as of September 14, 2025.

Who are the new independent directors elected to DexCom's board?

Kevin J. McNamara and Steven J. Shulman have been elected as new independent directors.

What is DexCom, Inc.'s principal executive office address?

DexCom, Inc.'s principal executive offices are located at 6340 Sequence Drive, San Diego, CA 92121.

What is the exact date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is September 14, 2025.

Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-09-15 19:30:47

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DEXCOM, INC. By: /s/ JEREME M. SYLVAIN Jereme M. Sylvain Executive Vice President, Chief Financial Officer Date: September 15, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing